IRF4 translocation status in pediatric follicular and diffuse large B-cell lymphoma patients enrolled in Children's Oncology Group trials

Karen M. Chisholm, Jeffrey Mohlman, Michael Liew, Amanda Termuhlen, Mitchell S. Cairo, Thomas G. Gross, Sherrie L. Perkins, Rodney R. Miles

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Large B-cell lymphoma with IRF4 rearrangement is a provisional entity in the 2017 World Health Organization classification. In order to characterize these lymphomas in children from the United States, IRF4 FISH and immunohistochemical stains were performed on 32 follicular lymphoma and diffuse large B-cell lymphoma (DLBCL) from Children's Oncology Group studies. Two DLBCLs (6%) had IRF4 rearrangements, one involving the ileocecal valve and another involving the tonsil and cerebrospinal fluid. Both cases had strong, diffuse IRF4/MUM1 immunohistochemical staining, which may be a pathologic clue to the diagnosis. Reclassification of these cases may have prognostic and therapeutic implications.

Original languageEnglish (US)
Article numbere27770
JournalPediatric Blood and Cancer
Volume66
Issue number8
DOIs
StatePublished - Aug 2019

Bibliographical note

Funding Information:
Samples from Children's Oncology Group rare NHL registry ANHL04B1 and COG B-NHL trials ANHL1131 and CCG-5961 were used in this study (COG protocol #ANHL16B2-Q and #ANHL16B3-Q) and we acknowledge the following COG grants associated with the research: NCTN Operations Center Grant U10 CA180886, NCTN Statistics and Data Center Grant U10 CA180899, and Human Specimen Banking in NCI-Sponsored Clinical Trials U24CA114766. This research is also supported by St. Baldrick's Foundation. We thank the patients, families, physicians, and institutions who participated in these COG studies. We also thank the dedicated members of the Immunohistochemistry Laboratory at ARUP Laboratories for performing the immunohistochemical stains. This work was supported by the ARUP Institute for Clinical and Experimental Pathology, William L. Roberts Memorial Fund.

Funding Information:
NCTN Statistics and Data Center Grant, Grant/Award Number: U10 CA180899; NCTN Operations Center Grant, Grant/Award Number: U10 CA180886; Human Specimen Banking in NCI-Sponsored Clinical Trials, Grant/Award Number:U24CA114766;WilliamL.Roberts Memorial Fund, ARUP Institute for Clinical and Experimental Pathology; St. Baldrick’s Foundation

Funding Information:
Samples from Children’s Oncology Group rare NHL registry ANHL04B1 and COG B-NHL trials ANHL1131 and CCG-5961 were used in this study (COG protocol #ANHL16B2-Q and #ANHL16B3-Q) and we acknowledge the following COG grants associated with the research: NCTN Operations Center Grant U10 CA180886, NCTN Statistics and Data Center Grant U10 CA180899, and Human Specimen Banking in NCI-Sponsored Clinical Trials U24CA114766. This research is also supported by St. Baldrick’s Foundation. We thank the patients, families, physicians, and institutions who participated in these COG studies. We also thank the dedicated members of the Immunohistochemistry Laboratory at ARUP Laboratories for performing the immunohistochemical stains. This work was supported by the ARUP Institute for Clinical and Experimental Pathology, William L. Roberts Memorial Fund.

Publisher Copyright:
© 2019 Wiley Periodicals, Inc.

Keywords

  • diffuse large B-cell lymphoma
  • follicular lymphoma, IRF4
  • lymphoma
  • pediatric

Fingerprint Dive into the research topics of 'IRF4 translocation status in pediatric follicular and diffuse large B-cell lymphoma patients enrolled in Children's Oncology Group trials'. Together they form a unique fingerprint.

Cite this